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Immune Phenotype and Function
of Natural Killer and T Cells in
Chronic Hepatitis C Patients Who
Received a Single Dose of
Anti-MicroRNA-122, RG-101
Femke Stelma,1,2 Meike H. van der Ree,1,2 Marjan J. Sinnige,2 Anthony Brown,3 Leo Swadling,3 J. Marleen L. de Vree,4
Sophie B. Willemse,1 Marc van der Valk,1 Paul Grint,5 Steven Neben,5 Paul Klenerman,3 Eleanor Barnes,3
Neeltje A. Kootstra,2 and Hendrik W. Reesink1
MicroRNA-122 is an important host factor for the hepatitis C virus (HCV). Treatment with RG-101, an N-acetylgalac-
tosamine-conjugated anti-microRNA-122 oligonucleotide, resulted in a signiﬁcant viral load reduction in patients with
chronic HCV infection. Here, we analyzed the effects of RG-101 therapy on antiviral immunity. Thirty-two chronic
HCV patients infected with HCV genotypes 1, 3, and 4 received a single subcutaneous administration of RG-101 at 2
mg/kg (n 5 14) or 4 mg/kg (n 5 14) or received a placebo (n 5 2/dosing group). Plasma and peripheral blood mononu-
clear cells were collected at multiple time points, and comprehensive immunological analyses were performed. Following
RG-101 administration, HCV RNA declined in all patients (mean decline at week 2, 3.27 log10 IU/mL). At week
8 HCV RNA was undetectable in 15/28 patients. Plasma interferon-c-induced protein 10 (IP-10) levels declined signiﬁ-
cantly upon dosing with RG-101. Furthermore, the frequency of natural killer (NK) cells increased, the proportion of NK
cells expressing activating receptors normalized, and NK cell interferon-c production decreased after RG-101 dosing.
Functional HCV-speciﬁc interferon-c T-cell responses did not signiﬁcantly change in patients who had undetectable
HCV RNA levels by week 8 post–RG-101 injection. No increase in the magnitude of HCV-speciﬁc T-cell responses was
observed at later time points, including 3 patients who were HCV RNA–negative 76 weeks postdosing. Conclusion: Dosing
with RG-101 is associated with a restoration of NK-cell proportions and a decrease of NK cells expressing activation
receptors; however, the magnitude and functionality of ex vivo HCV-speciﬁc T-cell responses did not increase following
RG-101 injection, suggesting that NK cells, but not HCV adaptive immunity, may contribute to HCV viral control fol-
lowing RG-101 therapy. (HEPATOLOGY 2017;66:57-68).
Chronic hepatitis C (CHC) virus infection is aglobal health problem. Patients with CHCinfection are at increased risk of developing
liver-related complications such as hepatocellular carci-
noma and cirrhosis.(1) Successful hepatitis C virus
(HCV) treatment reduces the risk of complications
and improves survival.(2,3) Recently, direct-acting anti-
virals (DAAs) have become available, which can
directly interfere with the HCV viral machinery. These
DAAs have drastically changed the ﬁeld of CHC
Abbreviations: APC, allophycocyanin; CD, cluster of differentiation; CHC, chronic hepatitis C; CMV, cytomegalovirus; DAA, direct-acting antiviral;
ELISpot, Enzyme-Linked ImmunoSpot; FITC, ﬂuorescein isothiocyanate; HCV, hepatitis C virus; HLA, human leukocyte antigen; IFN, interferon;
IL, interleukin; IP-10, IFN-c-induced protein 10; LLOQ, lower limit of quantiﬁcation; miR-122, microRNA-122; NK, natural killer; PBMC,
peripheral blood mononuclear cell; PE, phycoerythrin; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand.
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treatment by achieving sustained virological response
in a high proportion of patients.(4) With such high
cure rates for HCV, the next challenge of research
needs to focus on vaccine development and optimizing
current treatment regimens and delivering them cost-
effectively.(5) The cost of DAAs is considerable, and
combining DAAs with compounds that have a differ-
ent mechanism of action may reduce both duration
and cost of treatment. An alternative therapeutic
option lies in inhibition of an important host factor
used by HCV, microRNA-122 (miR-122).
miR-122 is a highly conserved, liver-speciﬁc micro-
RNA which has important functions in the regulation
of cholesterol and fatty acid synthesis.(6) In addition,
miR-122 can bind to the HCV genome and thereby
promote virus replication.(7,8) Targeting this host fac-
tor with an antisense oligonucleotide has proven effec-
tive at inhibiting HCV across several genotypes.(9-11)
A single subcutaneous dose of the N-acetylgalactos-
amine-conjugated anti-miR-122 oligonucleotide RG-
101 resulted in substantial decreases in HCV RNA in
all treated patients and HCV RNA negativity for at
least 76 weeks in 3 patients.(9)
The exact mechanism of HCV inhibition by RG-101
is not yet known. As binding of miR-122 protects HCV
RNA from degradation by exonucleases, blocking miR-
122 could uncover the genome to these innate defense
pathways.(8,12-14) Furthermore, HCV RNA replication
could be disturbed by knocking down miR-122.(14,15)
Inhibition of HCV replication may lead to natural killer
(NK) cell normalization.(16,17) Furthermore, a reduction
in viral antigen expression could restore HCV-speciﬁc
T-cell responses and thereby contribute to viral clearance.
Because all former treatment options included
interferon-alfa, an immune modulator, the effects of
new therapies on the immune system are substantially
different. Exogenous interferon-alfa treatment of
patients with CHC enhanced interferon (IFN)–stimu-
lated gene expression and activated NK cells but did
not lead to recovery of the T-cell compartment.(18-20)
The inhibition of host factor miR-122 by RG-101 acts
through a different mechanism and could potentially
restore antiviral immunity.
The aim of this study was to investigate whether
treatment with RG-101 would change important
immune effectors in CHC infection and whether
restored antiviral immunity could play a role in long-
term virologic impact observed in patients treated with
a single dose of RG-101.
Patients and Methods
PATIENTS
We included 32 CHC patients at two sites in The
Netherlands (Academic Medical Center Amsterdam
and University Medical Center Groningen) (Table 1).
Males and postmenopausal females with chronic HCV
genotype 1, 3, or 4 infection were enrolled. Patients were
treatment-naive or had previously experienced a
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virological relapse after IFN-based therapy. Patients
with coinfection (hepatitis B virus or human immuno-
deﬁciency virus infection), evidence of decompensated
liver disease, or a history of hepatocellular carcinoma
were excluded. The study was approved by the regula-
tory authority and the independent ethics committee
at each participating site. All patients gave written
informed consent, and the study was conducted in
accordance with the Declaration of Helsinki, good
clinical practice guidelines, and local regulatory
requirements. All authors had access to the study data
and reviewed and approved the ﬁnal manuscript.
STUDY
In this randomized, double-blind, placebo-
controlled, phase 1b trial,(21) patients received a single
subcutaneous injection of RG-101, an N-acetylgalactos-
amine-conjugated oligonucleotide antagonizing miR-
122 (EudraCT no. 2013-002978-49). Dosage was 2
mg/kg (n5 14) or 4 mg/kg (n 5 14), and 2 patients in
each group received placebo. The initial follow-up was
8 weeks after dosing. At week 8, only patients with a
>2 log 10 decrease from baseline and a <1 log 10
increase in HCV RNA level from nadir were included
in an extended follow-up study (n 5 22, including n 5
10 at 2 mg/kg and n 5 12 at 4 mg/kg); of these, 15
patients (n 5 6 at 2 mg/kg and n 5 9 at 4 mg/kg) had
HCV RNA levels below the lower limit of quantiﬁca-
tion (<LLOQ) at week 8. Patients who did not meet
the above criteria were excluded from the study at week
8 (n 5 10, including placebo-treated patients). The
extended follow-up lasted until week 76 (Supporting
Fig. S1). If patients had a virological rebound (deﬁned
as a >1 log 10 increase) during follow-up, a retest was
performed, after which patients were excluded from the
study. In the extended follow-up, rebounds occurred at
week 12 (n 5 8), week 16 (n 5 2), week 20 (n 5 1),
week 28 (n 5 2), week 36 (n 5 2), and week 52 (n 5
1); and 3 patients were lost to follow-up (Supporting
Fig. S2). At week 76, 3 patients had undetectable HCV
RNA levels after a single dose of RG-101. HCV RNA
levels were measured using the Roche COBAS Ampli-
Prep/COBAS TaqMan HCV v2.0 assay, with a
reported LLOQ of 15 IU/mL.
SAMPLING
Plasma samples from CHC patients for cytokine
analyses were collected at baseline, day 3, and weeks 1,
4, and 8. For comparison, healthy control plasma (n 5
6) was added (not matched for age, gender, or
TABLE 1. Baseline Characteristics
RG-101 (n 5 28)
2 mg/kg 4 mg/kg
Placebo
(n 5 4) Total
Total (n) 14 14 4 32
Male (n) 13 7 4 24 (75)
Age (years) 51 (46-53) 54 (48-58) 55 (52-57) 52 (49-57)
Weight (kg) 84 (71-98) 83 (69-89) 79 (74-83) 83 (72-92)
Ethnicity (n)
Caucasian 13 12 4 29 (91)
Asian 1 1 0 2 (6)
Other 0 1 0 1 (3)
IFNL3 CC genotype (n) 3 3 2 8 (25)
IFN naive* (n) 9 12 3 24 (75)











1a 8 4 2 14 (44)
1b 1 1 0 2 (6)
3 4 5 1 10 (31)
4 1 4 1 6 (19)
Alanine aminotransferase
level (U/L)









HLA-A21 (n) 4 5 2 11 (34)
Data are given as median (interquartile range) or as frequency (percentage).
*Naive to IFN-a-based therapy.
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ethnicity). Peripheral blood mononuclear cells
(PBMCs) were collected at baseline; weeks 2, 8, 20,
28, and 52; time of viral rebound or retest (between
weeks 12 and 52); and end of follow-up (week 76)
(Supporting Fig. S1). PBMCs from healthy blood
donors were used as heathy controls (n 5 13). PBMCs
were separated by density gradient and cryopreserved
for later analyses.
LUMINEX ANALYSES
Plasma cytokine levels were measured using a Lumi-
nex 20-plex immunoassay (Affymetrix; eBioscience,
San Diego, CA). This included interleukin-12
(IL-12); chemokine (C-C motif) ligands 2, 3, and 4;
cluster of differentiation 54 (CD54); IFN-c-induced
protein 10 (IP-10 or chemokine [C-X-C motif] ligand
10), granulocyte-macrophage colony-stimulating
factor, IFN-a, IFN-c, IL-1a, IL-1b, IL-10, IL-13,
IL-17A, IL-4, IL-6, IL-8, sCD62E, sCD62P, and
tumor necrosis factor-a. Plasma levels of IL-18 were
measured with a DuoSet enzyme-linked immunosor-
bent assay (R&D Systems, Minneapolis, MN). Plasma
samples from 6 healthy controls were included in the
analyses.
FLOW CYTOMETRY
PBMCs were thawed and stained for 30 minutes at
48C with different combinations of ﬂuorescently
labeled, conjugated mouse antihuman monoclonal
antibodies; CD56 BUV-395, CD27 BUV-373,
human leukocyte antigen (HLA)-DR ﬂuorescein iso-
thiocyanate (FITC), CD3 V500, CD16 BV786,
CD16 BV421, CD14 phycoerythrin (PE)-CF594,
CD19 PE-CF594, CD38 PE-Cy7 (BD Biosciences,
San Jose, CA), NKp46 PerCP-eﬂuor710, CD45RA
eFluor 605NC (eBioscience) CXCR6 BV-421, CD8
BV-711, CD8 BV-785, NKp30 allophycocyanin
(APC) (Biolegend, San Diego, CA), Live/Dead ﬁx-
able dead cell stain RED (Invitrogen, Life Technolo-
gies, Carlsbad, CA), NKG2A PE (Beckman Coulter,
Fullerton, CA), and tumor necrosis factor–related
apoptosis-inducing ligand (TRAIL)/CD253 APC
(Miltenyi Biotec, Bergisch Gladbach, Germany).
For intracellular staining, cells were ﬁxed after sur-
face staining, permeabilized (FoxP3/transcription fac-
tor staining buffer set; eBioscience), and stained with
monoclonal antibodies; perforin FITC (BD Biosci-
ences) Eomes PerCP-eﬂuor710, T-bet PE-Cy7
(eBioscience), Ki67 BV711 (Biolegend), and Gran-
zyme B PE (Sanquin, Amsterdam, The Netherlands).
Ex vivo CD81 T-cell frequencies were determined
in HLA-A2-positive patients (n 5 11 patients: geno-
types 1a, n 5 6; 3a, n 5 3; 4a, n 5 1; and 4d, n 5 1)
by HLA class I multimers. Multimers were loaded
with dominant epitopes NS31073-1081 (CINGVCWTV;
APC) (Sanquin), NS41406-1415 (KLVALGINAV)
(PE), and NS5B2594-2602 (ALYDVVTKL) (FITC)
(Immudex, Copenhagen, Denmark). Gating was based
on the background level observed in healthy non-
HCV-infected controls (Supporting Fig. S3). As con-
trol, we stained for cytomegalovirus (CMV)–pp65495-
504 (NLVPMVATV) and Epstein-Barr virus BMLF-
1259-267 (GLCTLVAML) tetramers (Sanquin). All
measurements were performed on an LSR
Fortessa cytometer (BD Biosciences) and analyzed by
FlowJoMacV9.7.5 software.
NK-CELL FUNCTION
Patients were selected when samples were available
for day 1 as well as week 8 (n 5 13), and healthy blood
donors (n 5 13) were added as controls. PBMCs were
thawed and incubated overnight with IL-12 and
IL-15 or no stimulus in the presence of CD107a
FITC (eBioscience). For the last 3 hours, monensin
and brefeldin A were added, after which cells were
stained with live/dead stain, CD3 V500, and CD56
BUV-395 as above. After ﬁxing the cells, intracellular
staining was performed (IFN-c BV421, tumor necro-
sis factor-a AF700, macrophage inﬂammatory
protein-1b Pe-Cy7; BD Biosciences), and measure-
ments were done on an LSR Fortessa. The proportion
of IL-12/IL-15 activated cells was calculated by sub-





assays were performed ex vivo in duplicate at 2 3 105
PBMCs/well. Thawed PBMCs were rested overnight
(378C 1 CO2) and stimulated with panels of 15-mer
peptides that overlapped by 11 amino acids corre-
sponding to HCV genotype 1a, 1b, 3a, or 4a
(described in Barnes et al.(22) and Kelly et al.(23)).
Patient PBMCs were stimulated with the panel of
peptides that matched their own viral genotype and
subtype (where possible). Peptides were arranged into
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10 pools corresponding to core, E1, E2, P7&NS2,
NS3p, NS3h, NS4, NS5A, NS5B I, and NS5B II.
Each peptide was used at a ﬁnal concentration of 3 lg/
mL. Internal controls were dimethyl sulfoxide (Sigma-
Aldrich, UK) as a negative control and concanavalin A
(Sigma-Aldrich) as a positive control. Other antigens
used were a pool of major histocompatibility complex
class 1–restricted epitopes of inﬂuenza A, Epstein-
Barr virus, and CMV (BEI Resources, Manassas, VA)
and a lysate of CMV-infected cells (Virusys Corp,
Taneytown, MD). Spot-forming units were calculated
per 106 PBMCs and background levels subtracted.
Positive responses were deﬁned as (1) the mean of
responses to a pool minus background being greater
than 48 spot-forming units/106 PBMCs and (2) the
mean of responses to a well exceeding 3 times the
background. The background level of 48 spot-forming
units/106 PBMCs/pool was determined previously in
74 healthy controls, which was the mean 1 3 standard
deviations.(22)
STATISTICAL ANALYSES
For differences between groups, the t test (normal
distribution) or Mann-Whitney test (non-normal dis-
tribution) was used. For longitudinal analysis in indi-
vidual patients, the Wilcoxon signed rank test was
used. P < 0.05 was considered statistically signiﬁcant.
GraphPad Prism version 6.07 for Windows (Graph-
Pad Software, La Jolla, CA) was used for analyses.
Results
IP-10 LEVELS DECREASE IN
PATIENTS DOSED WITH RG-101
HCV RNA levels declined in all patients dosed
with RG-101 (n 5 28). At week 4, the mean reduc-
tion was 4.1 log10 IU/mL in patients dosed with 2
mg/kg and 4.8 log10 IU/mL in patients dosed with 4
mg/kg compared to 0.0 log10 IU/mL in placebo-
treated patients (Fig. 1A). Plasma IP-10 and IL-18
levels were signiﬁcantly higher in CHC patients at
baseline compared to healthy controls (for IP-10,
median 58.1 pg/mL and 19.3 pg/mL, P < 0.0001; for
IL-18, 322.1 pg/mL and 140.9 pg/mL, P < 0.0001;
Fig. 1B), and no signiﬁcant differences were observed
within the three groups of CHC patients at baseline
(placebo, 2 mg/kg, and 4 mg/kg; data not shown).
IP-10 levels decreased signiﬁcantly in patients dosed
with RG-101 (Fig. 1C). At week 1, the median
decline in IP-10 levels was 23.9 pg/mL in 2 mg/kg–
dosed patients, 42.3 pg/mL in 4 mg/kg–treated
patients (P 5 0.02 and P 5 0.007 compared to place-
bo, respectively), and 1.4 pg/mL in placebo-treated
patients. IL-18 levels, however, increased after dosing
with RG-101 (Supporting Fig. S4). Of 28 patients, 15
had undetectable HCV RNA 8 weeks postdosing, and
IP-10 levels signiﬁcantly decreased in both of these
groups (Fig. 1D). However, IL-18 levels only signiﬁ-
cantly increased in the group of patients who had
HCV RNA levels <LLOQ at week 8 (Fig. 1D).
None of the other measured cytokines or chemokines
showed a signiﬁcant change upon dosing with RG-
101, including IFN-c, IFN-a, tumor necrosis factor-a,
and IL12p70 (Supporting Fig. S4).
TRAIL EXPRESSION DECREASES
ON CD56bright NK CELLS
At baseline, CHC patients and healthy controls had
comparable frequencies of NK cells in the blood
(median 7.4% and 7.0%, respectively, P 5 0.71; Fig.
2A; full gating in Supporting Fig. S5A). In patients
dosed with RG-101, the proportion of NK cells
increased signiﬁcantly from baseline 7.4% to median
10.1% (P 5 0.02) at week 8 and 10.3% at follow-up
week 12-28 (which included patients with viral
rebound deﬁned as a >1 log increase in viral load from
nadir between weeks 12 and 28 and patients with
HCV RNA <LLOQ at week 28; n 5 5, P 5 0.02).
In placebo-treated patients, no changes were observed
in NK-cell proportions during follow-up (Fig. 2A).
Furthermore, no changes in lymphocyte count were
observed in the blood (Supporting Fig. S5B). Patients
who had HCV RNA levels <LLOQ at week 8 had
signiﬁcantly lower proportions of NK cells compared
to patients who had HCV RNA >LLOQ at week
8 (8.4% and 13.1% respectively, P 5 0.01; Fig. 2A).
NK cells can be divided into two subsets, depending
on their expression of CD56: CD56bright and
CD56dim NK cells (Fig. 2B). Upon dosing, CD56dim
NK cells signiﬁcantly increased from median 91.7% to
94.8% at weeks 12-28 (P 5 0.0007), whereas
CD56bright NK cells decreased (median 8.3% at base-
line and 4.8% at follow-up week 12-28, P 5 0.001;
Fig. 2B). Expression of TRAIL on CD56bright NK
cells was signiﬁcantly up-regulated in CHC patients at
baseline compared to healthy controls (median 13.3%
and 7.3% of CD56bright NK cells, respectively, P 5
0.001; Fig. 2C). TRAIL expression signiﬁcantly
decreased as soon as week 2 in patients upon dosing
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with RG-101 (from median 13.3% at baseline to 6.4%
of CD56bright NK cells at week 2, P < 0.0001; Fig.
2C,D). No changes in TRAIL expression were
observed in placebo-treated patients (not shown). No
difference in TRAIL expression was observed in
patients who had HCV RNA levels <LLOQ versus
patients who had HCV RNA levels >LLOQ at week
8 (Fig. 2C, green and red dots).
DECREASED EXPRESSION OF NK
CELL–ACTIVATION RECEPTORS
In CHC patients, expression of Fcc receptor CD16
on NK cells was signiﬁcantly higher compared to
healthy controls (median 80.8% and 74.9%, respective-
ly, P 5 0.04), and this decreased after dosing with
RG-101 (80.8% at baseline to 77.0% at week 8, P 5
0.0019; Fig. 3A). Furthermore, expression of
activating receptors NKp30 and NKp46 on NK cells
decreased in patients who were dosed with RG-101
(NKp30, 75.0% at baseline to 62.8% at week 8, P 5
0.01; and NKp46, 74% at baseline and 67.2% at week
8, P 5 0.01; Fig. 3B,C). Expression of T-box tran-
scription factors T-bet and Eomes decreased upon
dosing with RG-101 (from 94.7% at baseline to 89.2%
at week 8 for T-bet, P 5 0.0003, and from 74.6% to
60.8% for Eomes, P 5 0.001; Fig. 3D,E), whereas
NK-cell IFN-c production signiﬁcantly decreased
(Supporting Fig. S6). Expression of the cell cycle
marker Ki67 in CHC patients was 5.9% at baseline
and signiﬁcantly decreased at week 2 (3.8%, P <
0.0001) and week 8 (4.9%, P 5 0.02) (Fig. 3F). Other
markers expressed on NK cells showed minor or no
changes (Supporting Fig. S7). Changes in T-bet,
Eomes, and Ki67 expression were also observed in the
CD81 T-cell and CD561 NK T-cell compartments
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FIG. 1. (A) Mean change in HCV RNA levels between baseline and week 4 in patients dosed with placebo (black dots) or with
RG-101 at 2 mg/kg (blue dots) and 4 mg/kg (red dots). (B) Plasma IP-10 and IL-18 levels in healthy controls and CHC patients at
baseline; bars indicate median. (C) Change in plasma IP-10 levels (median) in patients dosed with placebo (black dots) or with RG-
101 at 2 mg/kg (blue dots) and 4 mg/kg (red dots); level of signiﬁcant difference indicated between RG-101-dosed (2 mg/kg and 4
mg/kg) and placebo-dosed patients. (D) Plasma IP-10 and IL-18 levels at baseline and week 8 in patients with HCV RNA levels
<LLOQ and >LLOQ at week 8. Statistical testing: Mann-Whitney test (B,C) and Wilcoxon matched pairs test (D). *P < 0.05;
**P < 0.01; ***P < 0.001. Abbreviations: BL, baseline; HC, healthy control; ns, not signiﬁcant; SEM, standard error of the mean.
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(Supporting Fig. S8). No differences were observed
between patients with HCV RNA levels <LLOQ and
patients with HCV RNA levels >LLOQ at week
8 (Fig. 3A-F).
HCV-SPECIFIC T-CELL
RESPONSES DID NOT CHANGE
IN PATIENTS DOSED WITH
RG-101
Next, we investigated whether HCV-speciﬁc T cells
play a role in the (long-term) viral load reduction after
RG-101 dosing. The frequency of HCV-speciﬁc T
cells was measured in all HLA-A21 patients (n 5 11,
including 2 placebo-treated patients). Baseline ex vivo
HCV-speciﬁc CD81 T-cell frequencies were low
in CHC patients (median 0.009%, range 0%-0.21%;
Fig. 4A) and did not change upon dosing with RG-
101 (median 0.008%, range 0%-0.19% at week 2 and
median 0.007%, range 0%-0.05% at week 8; P 5 not
signiﬁcant) or in patients who received placebo (Sup-
porting Fig. S9A). Similarly, CMV-speciﬁc and
Epstein-Barr virus–speciﬁc T-cell proportions did not
change upon dosing with RG-101 (Supporting Fig.
S9B). The functional capacity of HCV-speciﬁc T cells,
as measured by IFN-c-ELISpot, did not change sig-
niﬁcantly in patients who were treated with RG-101
compared to placebo (Fig. 4B). Baseline IFN-c T-cell
responses were low in patients with CHC (with 8/32
patients having positive responses), and there was no
difference in the baseline T-cell responses of patients
who had HCV RNA levels <LLOQ and patients who
were HCV RNA–positive at week 8 (P 5 0.56)
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FIG. 2. (A) Proportion of NK cells as a percentage of total lymphocytes in healthy controls and CHC patients dosed with RG-101 at
baseline and weeks 2, 8, and 12-28 (including patients with viral rebound between weeks 12 and 28 and patients with HCV RNA
<LLOQ at week 28). Data are grouped in patients who are HCV RNA–positive (in red) or have HCV RNA levels <LLOQ (in green),
as well as in patients receiving placebo (in gray); bars indicate median. (B) Proportion of CD56bright and CD56dim cells as a percentage of
total NK cells in RG-101-dosed patients at baseline and weeks 2, 8, and 12-28; bars indicate median. Representative dot plot showing
NK-cell gating in total lymphocyte population. CD56bright and CD56dim NK-cell gates are shown. (C) Percentage of TRAIL1 cells within
CD56bright NK cells in healthy controls and patients dosed with RG-101; bars indicate median. The same groups as in (A) are used. (D)
Representative dot plot showing TRAIL gating; percentages of TRAIL1 cells within the CD56bright NK-cell population (black) are shown.
CD56dim NK cells are shown in gray for comparison. Statistical testing: Mann-Whitney test (A,C) and Wilcoxon matched pairs test
(B,C). *P < 0.05; **P < 0.01; ***P < 0.001 ****P < 0.0001. Abbreviations: BL/bl, baseline; HC, healthy control; ns, not signiﬁcant.
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(Fig. 4C). Furthermore, no changes were observed in
IFN-c T-cell responses between baseline and week
8 in patients who had HCV RNA levels <LLOQ at
week 8 (P 5 0.13) or HCV RNA levels >LLOQ at
week 8 (P 5 0.88) (Fig. 4D).
Three patients were tested HCV RNA–negative up
to 76 weeks after dosing with RG-101. In addition, 5
patients had a late viral rebound at week 28 (n 5 2),
week 36 (n 5 2), and week 52 (n 5 1). In none of
these patients was an increase in HCV-speciﬁc T-cell
responses observed (Fig. 5).
Discussion
In this unique phase 1b study we assessed the effects
of dosing with the N-acetylgalactosamine-conjugated
anti-miR-122 oligonucleotide RG-101 on antiviral
immunity in CHC patients in humans. We show that,
after a single monotherapy dose of RG-101, as a con-
sequence of HCV RNA decline, IP-10 levels decrease,
NK-cell proportions increase, and expression of NK
cell–activation receptors decreases. Furthermore,
NK-cell IFN-c production signiﬁcantly decreased, and
no restoration of ex vivo HCV-speciﬁc T-cell func-
tionality was observed after viral load decline or after
long-term HCV RNA negativity.
In CHC patients, continuous immune activation is
demonstrated by elevated levels of IFN-stimulated
genes, such as IP-10, and viral load suppression during
DAA treatment is associated with a decrease in IP-10
levels.(16,17,24) In patients who have viral relapse, IP-10
levels have been shown to increase again.(24) In our
study, IP-10 levels decreased in all patients who were
dosed with RG-101, irrespective of their treatment
outcome. We did not observe a subsequent increase in
IP-10 levels in patients who had experienced a viral
rebound; however, because patients were not followed
after rebound, IP-10 levels may have increased at a lat-
er time. Alternatively, RG-101 could induce other
mechanisms leading to IP-10 decrease, irrespective of
viral load decline.(25) In in vitro studies, miR-122 has
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FIG. 3. Proportion of (A) CD16, (B) NKp30, (C) NKp46, (D) T-bet, (E) Eomes, and (F) Ki67 in healthy controls as well as in CHC
patients dosed with RG-101 (n 5 28) at baseline and at weeks 2, 8, and 12-28 (including patients with viral rebound between weeks 12
and 28 and patients with HCV RNA <LLOQ at week 28); bars indicate median. Patients who have HCV RNA levels <LLOQ are
shown as green dots, and patients with HCV RNA levels >LLOQ are as red dots. Statistical testing: Mann-Whitney test (A-F, healthy
control versus CHC) and Wilcoxon matched pairs test (A-F). *P < 0.05; **P < 0.01; ***P < 0.001 ****P < 0.0001. Abbreviations: BL,
baseline; HC, healthy control; ns, not signiﬁcant.
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been shown to have proinﬂammatory effects, which
can be attenuated by inhibition with anti-miRNA-
122.(26) No other measured cytokines or chemokines
were altered in the plasma of patients dosed with RG-
101, which is consistent with preclinical data showing
that RG-101 does not elicit undesirable systemic
immune responses.(27)
NK cells play an important role in HCV infection.
NK cells signiﬁcantly increased in frequency in the
blood of patients after dosing with RG-101. Interest-
ingly, at week 8, the frequency of NK cells was higher
in patients who were HCV RNA–positive compared
to patients who had HCV RNA levels <LLOQ.
Possibly, a rebound in viral load with a subsequent rise
in IL-18 levels in these patients could have led to NK-
cell expansion. After RG-101 dosing, CD56bright NK
cells decreased, while CD56dim NK cells increased,
similar to data from DAA-treated patients.(17) TRAIL
is an important ligand expressed by NK cells which
can induce apoptosis in target cells through the
TRAIL receptor (TRAIL-R1 or TRAIL-R2). Target
cells include virally infected hepatocytes, which have
increased TRAIL receptor expression in CHC infec-
tion.(28) Furthermore, TRAIL expression on NK cells
is up-regulated in HCV-infected patients(29,30) and
has been shown to decrease upon viral load reduction
by DAA treatment.(16,17) We observed a similar
decrease in TRAIL expression on CD56bright NK cells
after a single dose of RG-101. In addition, expression
of the Fcc receptor CD16 as well as the cell cycle
marker Ki67 decreased in patients dosed with RG-
101, suggesting a reduction of the activated NK-cell
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FIG. 4. (A) Ex vivo multimer-positive cells as a proportion of total CD81 T cells in RG-101-dosed patients at baseline and weeks 2
and 8 (including n 5 2 HCV RNA <LLOQ, excluding n 5 2 due to missed visit). Each dot represents one epitope; a positive
response was deﬁned as more than 5 events with a lower threshold of 10,000 measured CD81 T cells; bars indicate median. (B) ELI-
Spot responses at baseline and week 8 in patients dosed with RG-101 (left) and placebo (right). Patients’ PBMCs were stimulated ex
vivo with genotype-speciﬁc HCV-peptide pools. (C) Baseline ELISpot responses in patients dosed with RG-101 with HCV RNA
levels >LLOQ (red, left) and <LLOQ (green, right) at week 8 and in patients receiving placebo. (D) IFN-c-ELISpot responses in
patients dosed with RG-101 who had HCV RNA levels >LLOQ (in red) and <LLOQ (in green). Statistical testing: Mann-
Whitney test (C) and Wilcoxon matched pairs test (A,B,D). Abbreviations: bl, baseline; ns, not signiﬁcant; SFU, spot-forming unit.
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FIG. 5. IFN-c-ELISpot responses in patients who were HCV RNA–negative for 76 weeks (upper graphs, patients 1-3) as well as in
patients who had HVC RNA levels <LLOQ for 20 or more weeks (lower graphs, patients 4-8). Responses considered above back-
ground (>48) are in color, and the other responses are in gray. *I Patient 4 had a <1 log10 increase in HCV RNA at week 20
(PBMC missing) and was negative again at week 24. Rebound was at week 28. *II Patient 5 had a >1 log10 increase in HCV RNA
at week 24 and a <1 log10 increase in HCV RNA at retest (week 26, last available PBMCs), and rebound was at week 36. Abbrevia-
tions: GT, genotype; SFU, spot-forming unit.
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phenotype. Other markers also indicated decreased
NK-cell activation upon RG-101 dosing, including
NKp30 and NKp46, which have been shown to
decrease upon DAA treatment,(17) and T-bet.(31) As
some of these changes in NK-cell markers showed
similar changes on bulk CD81 T cells and CD561
NK T cells, the observed changes in the NK-cell com-
partment might be the result of an overall decrease in
immune activation upon a decline in HCV viral load.
However, as miR-122 has been implicated in immune
regulation, direct effects of miR-122 inhibition could
also contribute to the changes in NK cells
observed.(25,26,32,33)
Chronic CHC infection leads to dysfunctional
(“exhausted”) HCV-speciﬁc CD81 T cells. In patients
successfully treated with IFN-free therapy, a restoration
of the proliferative capacity of these HCV-speciﬁc
CD81 T cells has been observed.(34) However, whether
the function of these HCV-speciﬁc CD81 T cells also
improves is unknown, as is whether restoration of HCV
immunity could contribute to HCV viral control. We
therefore analyzed HCV-speciﬁc CD81 T cells in RG-
101-dosed patients, and we did not observe an increase
in the ex vivo magnitude of HCV-speciﬁc CD81 T
cells as measured by HLA-A2-restricted multimers. To
overcome the limitation of only measuring three specif-
icities with multimers, which could be not optimally
genotype-matched(23) or could have undergone viral
escape, we subsequently analyzed T-cell functionality by
stimulating with overlapping peptide pools and assessing
IFN-c production in ELISpot assays. This also allowed
us to measure the functionality of both CD81 and
CD41 HCV-speciﬁc T cells. The magnitude of HCV-
speciﬁc T-cell responses did not change in patients who
were HCV RNA–negative at week 8, suggesting that T
cells do not contribute to HCV RNA decline after RG-
101 dosing. In line with this, we observed no speciﬁc
change in HCV-speciﬁc T-cell responses in patients
who were long-term HCV RNA–negative, suggesting
that other mechanisms play a role in the long-term viral
load reduction after RG-101 dosing.
In conclusion, one dose of anti-miR-122 RG-101
led to a decrease in HCV RNA levels in all patients
and sustained virological response >76 weeks in 3
patients. Dosing with RG-101 does not elicit systemic
immune activation. A decrease in IP-10 levels and
normalization of NK-cell phenotype were observed,
which are likely the result of HCV RNA decline. Last-
ly, our data suggest that HCV-speciﬁc T-cell recovery
does not play a role in the decline or long-term nega-
tivity of HCV RNA in patients dosed with RG-101.
Acknowledgment: The authors extend their grateful
thanks to Dr. E.B.M. Remmerswaal and Dr. B.
Hooibrink for technical assistance, and to all the par-
ticipating patients.
REFERENCES
1) Westbrook RH, Dusheiko G. Natural history of hepatitis C.
J Hepatol 2014;61(1 Suppl.):S58-S68.
2) van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H. Association
between sustained virological and advanced hepatic ﬁbrosis. J Am
Med Assoc 2012;308:2584-2593.
3) Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-
Ytter Y. Eradication of hepatitis C virus infection and the devel-
opment of hepatocellular carcinoma: a meta-analysis of observa-
tional studies. Ann Intern Med 2013;158:329-337.
4) Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies,
and challenges. Gastroenterology 2014;146:1176-1192.
5) Lindenbach BD. What’s next for hepatitis C virus research?
HEPATOLOGY 2016;63:1408-1410.
6) Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M, et al.
miR-122 regulation of lipid metabolism revealed by in vivo anti-
sense targeting. Cell Metab 2006;3:87-98.
7) Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Mod-
ulation of hepatitis C virus RNA abundance by a liver-speciﬁc
microRNA. Science 2005;309:1577-1581.
8) Machlin ES, Sarnow P, Sagan SM. Masking the 50 terminal
nucleotides of the hepatitis C virus genome by an unconventional
microRNA-target RNA complex. Proc Natl Acad Sci USA
2011;108:3193-3198.
9) van der Ree MH, de Vree JM, Stelma F, Willemse S, van der
Valk M, Rietdijk S, et al. Safety, tolerability, and antiviral
effect of RG-101 in patients with chronic hepatitis C: a phase
1B, double-blind, randomised controlled trial. Lancet 2017;
6736:1-9.
10) Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-
Torres M, Patel K, et al. Treatment of HCV infection by target-
ing microRNA. N Engl J Med 2013;368:1685-1694.
11) Li Y-P, Gottwein JM, Scheel TK, Jensen TB, Bukh J. Micro-
RNA-122 antagonism against hepatitis C virus genotypes 1-6
and reduced efﬁcacy by host RNA insertion or mutations in
the HCV 50 UTR. Proc Natl Acad Sci USA 2011;108:4991-
4996.
12) Li Y, Yamane D, Lemon SM. Dissecting the roles of the 50
exoribonucleases Xrn1 and Xrn2 in restricting hepatitis C virus
replication. J Virol 2015;89:4857-4865.
13) Li Y, Masaki T, Yamane D, McGivern DR, Lemon SM. Com-
peting and noncompeting activities of miR-122 and the 50 exo-
nuclease Xrn1 in regulation of hepatitis C virus replication. Proc
Natl Acad Sci USA 2013;110:1881-1886.
14) Thibault PA, Huys A, Amador-Ca~nizares Y, Gailius JE, Pinel
DE, Wilson JA. Regulation of hepatitis C virus genome replica-
tion by Xrn1 and microRNA-122 binding to individual sites in
the 50 untranslated region. J Virol 2015;89:6294-6311.
15) Masaki T, Arend KC, Li Y, Yamane D, McGivern DR, Kato
T, et al. MiR-122 stimulates hepatitis C virus RNA synthesis by
altering the balance of viral RNAs engaged in replication versus
translation. Cell Host Microbe 2015;17:217-228.
16) Serti E, Chepa-Lotrea X, Kim YJ, Keane M, Fryzek N, Liang
TJ, et al. Successful interferon-free therapy of chronic hepatitis C
HEPATOLOGY, Vol. 66, No. 1, 2017 STELMA ET AL.
67
virus infection normalizes natural killer cell function. Gastroen-
terology 2015;149:190-200.
17) Spaan M, van Oord G, Kreefft K, Hou J, Hansen BE, Janssen
HL, et al. Immunological analysis during interferon-free therapy
for chronic hepatitis C virus infection reveals modulation of the
natural killer cell compartment. J Infect Dis 2016;213:216-223.
18) Feld JJ, Nanda S, Huang Y, Chen W, Cam M, Pusek SN, et al.
Hepatic gene expression during treatment with peginterferon and
ribavirin: identifying molecular pathways for treatment response.
HEPATOLOGY 2007;46:1548-1563.
19) Markova AA, Mihm U, Schlaphoff V, Lunemann S, Filmann
N, Bremer B, et al. PEG-IFN alpha but not ribavirin alters NK
cell phenotype and function in patients with chronic hepatitis C.
PLoS One 2014;9:e94512.
20) Barnes E, Harcourt G, Brown D, Lucas M, Phillips R,
Dusheiko G, et al. The dynamics of T-lymphocyte responses
during combination therapy for chronic hepatitis C virus infec-
tion. HEPATOLOGY 2002;36:743-754.
21) Stelma F, de Niet A, Tempelmans Plat-Sinnige MJ, Jansen L,
Takkenberg RB, Reesink HW, et al. Natural killer cell character-
istics in patients with chronic hepatitis B virus (HBV) infection
are associated with HBV surface antigen clearance after combina-
tion treatment with pegylated interferon alfa-2a and adefovir.
J Infect Dis 2015;212:1042-1051.
22) Barnes E, Folgori A, Capone S, Swadling L, Aston S, Kurioka
A, et al. Novel adenovirus-based vaccines induce broad and sus-
tained T cell responses to HCV in man. Sci Transl Med 2012;4:
115ra1.
23) Kelly C, Swadling L, Brown A, Capone S, Folgori A, Salio M,
et al. Cross-reactivity of hepatitis C virus speciﬁc vaccine-
induced T cells at immunodominant epitopes. Eur J Immunol
2015;45:309-316.
24) Meissner EG, Wu D, Osinusi A, Bon D, Virtaneva K,
Sturdevant D, et al. Endogenous intrahepatic IFNs and associa-
tion with IFN-free HCV treatment outcome. J Clin Invest 2014;
124:3352-3363.
25) Li A, Qian J, He J, Zhang Q, Zhai A, Song W, et al. Modula-
tion of miR-122 expression affects the interferon response in
human hepatoma cells. Mol Med Rep 2013;7:585-590.
26) Momen-Heravi F, Bala S, Kodys K, Szabo G. Exosomes
derived from alcohol-treated hepatocytes horizontally transfer liv-
er speciﬁc miRNA-122 and sensitize monocytes to LPS. Sci Rep
2015;5:9991.
27) Neben S, Liu K, Berman C, Tay J, Esau C, Kaiser R, et al.
Pharmacokinetics, pharmacodynamics, and toxicity proﬁle of
RG-101, a novel GalNAc-conjugated hepatocyte targeting inhib-
itor of micro-RNA-122, in rhodents and cynomolgus monkeys.
J Hepatol 2015;62(Suppl.):S684-S685.
28) Mundt B, K€uhnel F, Zender L, Paul Y, Tillmann H, Trautwein
C, et al. Involvement of TRAIL and its receptors in viral hepati-
tis. FASEB J 2003;17:94-96.
29) Wandrer F, Falk CS, John K, Skawran B, Manns MP, Schulze-
Osthoff K, et al. Interferon-mediated cytokine induction deter-
mines sustained virus control in chronic hepatitis C virus infec-
tion. J Infect Dis 2016;213:746-754.
30) Serti E, Park H, Keane M, O’Keefe AC, Rivera E, Liang TJ,
et al. Rapid decrease in hepatitis C viremia by direct acting anti-
virals improves the natural killer cell response to IFNa. Gut
2017;66:724-735.
31) Burchill MA, Golden-Mason L, Wind-Rotolo M, Rosen HR.
Memory re-differentiation and reduced lymphocyte activation in
chronic HCV-infected patients receiving direct-acting antivirals.
J Viral Hepat 2015;22:983-991.
32) Nakamura M, Kanda T, Sasaki R, Haga Y, Jiang X, Wu S,
et al. MicroRNA-122 inhibits the production of inﬂammatory
cytokines by targeting the PKR activator PACT in human
hepatic stellate cells. PLoS One 2015;10:e0144295.
33) Hsu SH, Wang B, Kota J, Yu J, Costinean S, Kutay H, et al.
Essential metabolic, anti-inﬂammatory, and anti-tumorigenic func-
tions of miR-122 in liver. J Clin Invest 2012;122:2871-2883.
34) Martin B, Hennecke N, Lohmann V, Kayser A, Neumann-Haefelin
C, Kukolj G, et al. Restoration of HCV-speciﬁc CD81 T-cell func-
tion by Interferon-free therapy. J Hepatol 2014;61:538-543.
Author names in bold designate shared co-ﬁrst
authorship.
Supporting Information
Additional Supporting Information may be found at
onlinelibrary.wiley.com/doi/10.1002/hep.29148/suppinfo.
STELMA ET AL. HEPATOLOGY, July 2017
68
